Aurora Spine Corporation Announces Record Second Quarter Financial Results

Executive Summary

• Aurora Spine Corporation reported financial results for the second quarter ended June 30, 2025, highlighting continued revenue growth and improved profitability metrics.
• Total revenues increased by 10.2% to $4.5 million, driven by higher procedure volumes in ambulatory surgical and pain centers, particularly for the ZIP and SiLO TFX products.
• The company achieved a positive EBITDAC of $141,745, a significant improvement from the previous quarter's loss, while net loss narrowed to $0.199 million.

Key Details

• Revenue: Q2 2025 revenues were $4.50 million, a 10.2% increase from $4.02 million in Q2 2024.
• Gross Margin: Gross margin was 62.2% for Q2 2025, compared to 62.4% in Q2 2024 and improved from Q1 2025.
• EBITDAC: Reported EBITDAC was $141,745, an improvement from $105,522 in Q2 2024 and a sequential increase from $(20,924) in Q1 2025.
• Net Loss: Net loss was $(0.199) million for Q2 2025, compared to $(0.154) million in Q2 2024. Basic and diluted loss per share was $(0.00).
• Operating Expenses: Total operating expenses were $2.97 million in Q2 2025 (up from $2.74 million in Q2 2024), primarily due to increased sales commissions, marketing, and insurance, partially offset by decreases in G&A and consulting fees. Non-cash expenses were $0.298 million.
• Product Milestones:
  • Surpassed 2,500 procedures using the SiLO™ SI Joint Fusion System.
  • Surpassed 1,500 surgeries using the DEXA-C™.
  • Published a clinical study demonstrating superior biomechanical performance of the SiLO TFX™ MIS Sacroiliac Joint Fixation System.
• Sales Trends:
  • Cervical sales increased 70% ($327,000) in the first half of 2025 compared to the same period in 2024, reaching $794,000, largely driven by the DEXA-C implant.
  • Lumbar implant sales declined 19% in the first half of 2025 compared to the same period in 2024, due to the phasing out of Ti-Nano PEEK lumbar cages and transition to DEXA technology.
• Product Launches:
  • Hydra A.E.R.O.™: Inventory procured and initial surgeries commenced in early Q3 2025 ahead of schedule.
  • DEXA-L: A new standalone lumbar cage integrating DEXA technology is expected to launch in Q3 2025.
• Balance Sheet Highlights (as of June 30, 2025):
  • Cash: $580,978
  • Total Assets: $11,567,657
  • Current Liabilities: $4,290,155
  • Share Capital: $27,720,815

Notable Quotes

• "Second quarter results continued to demonstrate growth and solid operational performance as we build our sales efforts in the marketplace and advance our proprietary products amongst medical professionals," said Trent Northcutt, CEO.
• "Financially speaking, the second quarter performed well, with over 10% increase in revenues and solid gross profit margins. While we seek to add more salespeople in strategic areas of the country, we continue to be diligent with our capital and tightly monitor all expenses to strive towards consistent profitability," said Chad Clouse, CFO.